MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics
under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche's oncology products to use Halozyme's Enhanze (recombinant human hyaluronidase) technology.
MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulation could potentially save time for patients, physicians and health care providers.